SCHEMBL4098064

SCHEMBL4098064

O=[C]c1cccc(NC=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
KCNA5 P22460 1/20 0.37
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTPN11 Q06124 1/20 0.35
IDO1 P14902 1/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 1/20 0.34
GRM4 Q14833 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29960515 0.84 ALDH1A1 (0.53) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL224028 0.84 ALDH1A1 (0.53) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL18993220 0.82 ALDH1A1 (0.48) ALDH1A1MAPTKMT2AMEN1IDO1
SCHEMBL12129057 0.80 ALDH1A1 (0.67) ALDH1A1MAPTKMT2AMEN1ALOX15
SCHEMBL10191908 0.79 ALDH1A1 (0.45) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL95531 0.75 TSHR (0.42) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL8724146 0.75 MAPT (0.43) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL7232634 0.74 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1HTTLMNA
SCHEMBL2320179 0.73 ALDH1A1 (0.60) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL28615947 0.73 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445516-B2 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-05-21 US disclosed
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-07-23 US disclosed
EP-1708705-B1 USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS OTSUKA PHARMA CO LTD (JP) 2009-02-18 EP disclosed
EP-1708705-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-10-11 EP disclosed
WO-2005072734-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-08-11 WO disclosed
US-3931142-A Heterocyclic containing disazo compounds CIBA-GEIGY AG (CH) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis FLT1, FLT4, KDR ALDH1A1 246/4885MAPT 4708/4885KMT2A 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.